H S Ho1, C F Frey. 1. Department of Surgery, University of California, Davis Medical Center, Sacramento, USA.
Abstract
OBJECTIVE: To assess the impact of intravenous (IV) antibiotic prophylaxis on the incidence of pancreatic infection and the mortality rate in severe acute pancreatitis. DESIGN: Restropective review of a cohort of 180 patients with severe acute pancreatitis. SETTING: A tertiary referral center in Sacramento, Calif. INTERVENTION: The use of IV antibiotic prophylaxis evolved during 3 periods from no antibiotics in 50 patients (1982-1989), to nonprotocol use in 55 patients (1990-1992), to a 4-week course of imipenem-cilastatin sodium (1993-1996) given to 75 patients having Acute Physiology and Chronic Health Evaluation (APACHE) II scores greater than 6 and pancreatic necrosis (> 15% of the gland), peripancreatic necrosis, or peripancreatic collection. MAIN OUTCOME MEASURES: Pancreatic infection and mortality. RESULTS: Without antibiotic prophylaxis, the incidence of pancreatic infection was 76% (38/50). Intravenous antibiotic prophylaxis reduced the infection rate of 45% (25/55) (P = .03). The imipenem-cilastatin protocol further reduced the infection rate to 27% (20/75) (P = .04). The mortality rates showed only a decreasing trend, from 16% (1982-1989) to 7% (1990-1992) to 5% (1993-1996) (P = .11). Patients with sterile severe acute pancreatitis had a mortality rate of 2% (2/97); whereas 17% (14/83) of patients with infection succumbed to the disease. Patients developing infection within the first 4 weeks from the onset of illness had mortality rates ranging from 19% to 40%, compared with 0% to 8% for those who became infected after 4 weeks. No patient with pancreatic infection developing after 4 weeks died with the imipenem-cilastatin protocol. CONCLUSIONS:Intravenous antibiotic prophylaxis significantly reduced the infection rate in severe acute pancreatitis, with only a trend toward improved survival. A prospective, randomized, double-blind multicenter trial comparing the efficacy of different types and/or combinations of antibiotic prophylaxis in severe acute pancreatitis is indicated.
RCT Entities:
OBJECTIVE: To assess the impact of intravenous (IV) antibiotic prophylaxis on the incidence of pancreatic infection and the mortality rate in severe acute pancreatitis. DESIGN: Restropective review of a cohort of 180 patients with severe acute pancreatitis. SETTING: A tertiary referral center in Sacramento, Calif. INTERVENTION: The use of IV antibiotic prophylaxis evolved during 3 periods from no antibiotics in 50 patients (1982-1989), to nonprotocol use in 55 patients (1990-1992), to a 4-week course of imipenem-cilastatin sodium (1993-1996) given to 75 patients having Acute Physiology and Chronic Health Evaluation (APACHE) II scores greater than 6 and pancreatic necrosis (> 15% of the gland), peripancreatic necrosis, or peripancreatic collection. MAIN OUTCOME MEASURES: Pancreatic infection and mortality. RESULTS: Without antibiotic prophylaxis, the incidence of pancreatic infection was 76% (38/50). Intravenous antibiotic prophylaxis reduced the infection rate of 45% (25/55) (P = .03). The imipenem-cilastatin protocol further reduced the infection rate to 27% (20/75) (P = .04). The mortality rates showed only a decreasing trend, from 16% (1982-1989) to 7% (1990-1992) to 5% (1993-1996) (P = .11). Patients with sterile severe acute pancreatitis had a mortality rate of 2% (2/97); whereas 17% (14/83) of patients with infection succumbed to the disease. Patients developing infection within the first 4 weeks from the onset of illness had mortality rates ranging from 19% to 40%, compared with 0% to 8% for those who became infected after 4 weeks. No patient with pancreatic infection developing after 4 weeks died with the imipenem-cilastatin protocol. CONCLUSIONS: Intravenous antibiotic prophylaxis significantly reduced the infection rate in severe acute pancreatitis, with only a trend toward improved survival. A prospective, randomized, double-blind multicenter trial comparing the efficacy of different types and/or combinations of antibiotic prophylaxis in severe acute pancreatitis is indicated.
Authors: Enrique Maraví-Poma; Joan Gener; Francisco Alvarez-Lerma; Pedro Olaechea; Armando Blanco; J Enrique Domínguez-Muñoz Journal: Intensive Care Med Date: 2003-10-10 Impact factor: 17.440
Authors: E Patchen Dellinger; Jose M Tellado; Norberto E Soto; Stanley W Ashley; Philip S Barie; Thierry Dugernier; Clement W Imrie; Colin D Johnson; Hanns-Peter Knaebel; Pierre-Francois Laterre; Enrique Maravi-Poma; Jorge J Olsina Kissler; Miguel Sanchez-Garcia; Stefan Utzolino Journal: Ann Surg Date: 2007-05 Impact factor: 12.969
Authors: A García-Barrasa; F G Borobia; R Pallares; R Jorba; I Poves; J Busquets; J Fabregat Journal: J Gastrointest Surg Date: 2008-12-11 Impact factor: 3.452